GlassScriptPhysician profile
John Kung
NPI 1497857080
$7,730.06
in general payments reported to CMS, 2019-2025
36 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $1,679 · 2021: $1,176 · 2022: $572 · 2023: $780 · 2024: $900 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104 · Honoraria: $25.59 · Gift: $3.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.89 |
| Honoraria | $25.59 |
| Gift | $3.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $1,486.57 | 2019-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Rxsight INC | $1,308.99 | 2020-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Alcon Vision LLC | $1,307.93 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Ivantis, INC | $965.22 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $442.09 | 2019-2025 | Tecnis Simplicity |
| Glaukos Corporation | $317.91 | 2022-2025 | Idose |
| Novartis Pharmaceuticals Corporation | $291.71 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $209.41 | 2019-2023 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $153.74 | 2019-2021 | |
| Harrow Eye, LLC | $136.43 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $120.26 | 2022-2024 | Envista Mx60 Iol, Miebo |
| Mallinckrodt Hospital Products INC. | $102.69 | 2020-2023 | Acthar |
| Ani Pharmaceuticals, INC. | $101.92 | 2024-2025 | Purified Cortrophin Gel |
| Dompe US, INC. | $91.38 | 2022-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $64.13 | 2023-2025 | Iyuzeh |
| Omeros Corporation | $51.68 | 2019 | |
| Kala Pharmaceuticals, INC. | $50.73 | 2019-2021 | |
| Oyster Point Pharma, INC. | $48.74 | 2023 | Tyrvaya |
| Allergan, INC. | $46.08 | 2019-2021 | |
| Horizon Therapeutics Plc | $39.91 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $37.91 | 2025 | Xdemvy |
| Akorn Operating Company LLC | $34.85 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $30.75 | 2021 | |
| Abbvie INC. | $30.32 | 2022-2023 | |
| Alimera Sciences, INC. | $28.32 | 2020 | |
| Biotissue Holdings INC. | $21.33 | 2022 | |
| Amgen INC. | $19.94 | 2024 | Tepezza |
| Genentech USA, INC. | $18.95 | 2022 | |
| Sandoz INC. | $17.36 | 2024 | Cimerli |
| Ocular Therapeutix, INC. | $17.13 | 2020 | |
| Halozyme INC | $15.58 | 2020 | |
| Shire North American Group INC | $14.74 | 2019 | |
| Rayner Intraocular Lenses Limited | $14.04 | 2022 | |
| Eyevance Pharmaceuticals LLC | $13.92 | 2022 | |
| Aerie Pharmaceuticals, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.